SITEMAP
News
- Category: News
- EU-RESPONSE second face-to-face consortium meeting
- Coordination of COVID-19 platform trials in Europe
- DisCoVery publishes a letter on Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
- Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
- DisCoVery publishes an article on association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients
- EU-RESPONSE supports a global meta-analysis on JAK inhibitors in hospitalized COVID-19 patients
- DisCoVery publishes an article on quality control in the context of the SARS-CoV 2 epidemic
- DisCoVery publishes an article on management of pharmacovigilance during the COVID-19 pandemic crisis
- EU-RESPONSE first face-to-face consortium meeting
- EU SolidAct publishes resuts on Baricitinib as a Treatment for Hospitalized COVID-19 Patients
- EU SolidAct continues, randomising only immunocompromised patients in the baricitinib trial
- remdesivir has a significant antiviral activity, reducing the amount of viral particles released by infected cells
- BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
- Remdesivir Ineffective in Patients Hospitalized With COVID-19 and the DisCoVeRy Trial Continues with a New Antiviral
- Launch of European Covid-19 trials coordination module website
- EU SolidAct – a pan-European platform for pandemic research and preparedness
- Inserm and AstraZeneca join forces to test the efficacy of monoclonal antibody combination AZD7442 on Covid-19 in the European DisCoVeRy trial
- Launch of the EU-RESPONSE project
- DisCoVeRy trial in practice